Goldman Sachs analyst Salveen Richter assigned of Enliven (ELVN) with a Buy rating and $37 price target from a previous Early-Stage Biotech designation. The firm cites the company’s continued positive Phase 1 data and the announcement of a planned Phase 3 initiation in 2026 for tyrosine kinase inhibitor ELVN-001 in chronic myeloid leukemia for the Buy rating. ELVN-001 remains well-tolerated, with no increased cardiovascular toxicity, and the data supports the potential for once daily dosing without the need for fasting and low drug-drug interactions, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating
- Adobe reports Q2 beat, Meta invests in Scale AI: Morning Buzz
- Enliven Therapeutics Announces Positive Phase 1 Trial Results
- Enliven announces $200M offering of common stock, warrants
- Enliven announces updated data from ELVN-001 trial